Sells filtration, chromatography and process-measurement systems and consumables for biological drug manufacturing to biopharmaceutical companies, contract manufacturers and other life-sciences companies.
10-K for FY2025, filed Feb 26, 2026As the overall market for biologics continues to grow and expand, our primary customers – global biopharmaceutical companies, contract…View ↗
Our bioprocessing business is comprised of four main franchises: Filtration (including Fluid Management); Chromatography; Process…View ↗
The majority of our revenue is derived from consumable and/or single-campaign (“single-use”) product sales, though we have grown our…View ↗
Biopharmaceutical and life-sciences customers buy bioprocessing products, equipment and related consumables; product sales are generally counted when the products are delivered to customers.
10-K for FY2025, filed Feb 26, 2026We generate revenue from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices…View ↗
The Company’s other filtration product offerings are not highly interdependent of one another and are therefore considered distinct…View ↗
The Company’s chromatography franchise includes a number of products used in the downstream purification and quality control of biological…View ↗
Through the acquisition of C Technologies, Inc. in 2019, the Company offers downstream PAT solutions. The Company added to the analytics…View ↗
Each protein product is considered distinct and therefore represents a separate performance obligation. Protein product revenue is…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$738.3M
10-K for FY2025, filed Feb 26, 2026
$738.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Revenue
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
100%
FY2022: 100%
|
Product Revenue, FY2025
$738M Sources
|
Sold outright |
|
Royalty and other revenue
|
<0.1%
FY2022: <0.1%
|
Royalty and other revenue, FY2025
$296K Sources
|
Biopharmaceutical companies and contract manufacturers, along with other life-sciences customers, use its products in biological drug production; diagnostics companies and laboratory researchers are also customers.
10-K for FY2025, filed Feb 26, 2026
Yes. It kept 7 cents of every revenue dollar as net income in FY2025 and turned 13 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 30, 2026
−$38.4MView ↗
10-Q for Q3 FY2026, filed Oct 30, 2026
Open tableView ↗
8-K, filed Sep 8, 2026
As previously disclosed, on July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of…View ↗
8-K, filed Jul 28, 2026
Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09View ↗
8-K, filed Jul 22, 2026
On July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of Merger (the “Merger…View ↗
Integrated customer offerings
The latest report describes a move from selling individual products toward offering a broader portfolio as integrated solutions across manufacturing steps; the older report describes its product franchises and products.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Feb 26, 2026
Broader process analytics
The older report lists process analytics as a franchise; the latest adds upstream process-monitoring devices to that offering through an acquired portfolio.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Feb 26, 2026Our bioprocessing business is comprised of four main franchises: filtration; chromatography; process analytics; and proteins.View ↗
Competes with Danaher, Thermo Fisher Scientific, MilliporeSigma, and Sartorius
10-K for FY2025, filed Feb 26, 2026We compete with several medium and small companies in each of our product categories as well as several large companies, including Danaher…View ↗
Loading...